Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Neuro-Immune Interactions at Barrier Surfaces.
Enhancement of Chemotactic Cell Aggregation by Haptotactic Cell-To-Cell Interaction.
Some recent advances in multiple sclerosis.
Social Support in Relation to Fatigue Symptoms Among Patients with Multiple Sclerosis.
Sema4A inhibits the therapeutic effect of IFN-β in EAE.
Betaseron (Interferon Beta-1b) for SC Injection
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
[Neurophysiology in Guillain-Barré syndrome].
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Novantrone
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis.
Glatiramer acetate induced hepatotoxicity.
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
Salvianolic acid B protects the myelin sheath around injured spinal cord axons.
Gordon Research Conference on Notch Signaling in Development, Regeneration & Disease
Antagonism of histamine H4 receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis.
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
Trimesta (Oral Estriol)
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
Interferon beta treatment of multiple sclerosis increases serum interleukin-7.
Management of women with multiple sclerosis through pregnancy and after childbirth.
Burden of neurological conditions in Canada.
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

Pages